RTW Biotech OpportunitiesLSE:RTW +2.68%36 Net Margin % is 99.12% as of Dec. 2025, which is 1% above its 10-year median of 98.22. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,580 Asset Management companies, RTW Biotech Opportunities ranks better than 69.68% on this metric.
The historical rank and industry rank for RTW Biotech Opportunities's Net Margin % or its related term are showing as below:
LSE:RTW'
s Net Margin % Range Over the Past 10 Years
Min: 88.25 Med: 98.22 Max: 108.02
Current: 97.73
LSE:RTW's Net Margin % is ranked better than 69.68% of 1580
companies
in the Asset Management industry
Industry Median: 84.895
vs LSE:RTW: 97.73
RTW Biotech Opportunities (LSE:RTW) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
RTW Biotech Opportunities Net Margin % Related Terms
RTW Biotech Opportunities Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, RTW Biotech Opportunities's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities Net Margin % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Net Margin % distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTW Biotech Opportunities (LSE:RTW) has a Net Margin % of 99.12% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on RTW Biotech Opportunities and its competitors. This is near median its historical median of 98.22. Over the past decade, RTW Biotech Opportunities' Net Margin % has ranged from 88.25 to 108.02. According to the industry distribution chart, RTW Biotech Opportunities ranks #479 out of 1580 companies in the Asset Management industry, placing it in the top 30.3%.
Is RTW Biotech Opportunities' Net Margin % too high?
RTW Biotech Opportunities' current Net Margin % of 99.12% is near median its 10-year median of 98.22. Over the past 10 years, this metric has ranged from a low of 88.25 to a high of 108.02. The Asset Management industry median Net Margin % is 84.90. RTW Biotech Opportunities' value of 99.12% is 16.8% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #479 out of 1580 companies in the Asset Management industry, which is above the industry midpoint. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Net Margin % compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #479 out of 1580 companies for Net Margin %. This puts RTW Biotech Opportunities in the upper half of its industry. The industry median Net Margin % is 84.90. RTW Biotech Opportunities' value of 99.12% is 16.8% above this benchmark. Historically, RTW Biotech Opportunities' own Net Margin % has ranged from 88.25 to 108.02 over the past decade. While the company's 10-year median is 98.22 vs. the industry median of 84.90, RTW Biotech Opportunities has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for an Asset Management company?
The median Net Margin % among Asset Management companies is 84.90, based on 1,580 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current Net Margin % of 99.12% is 16.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median Net Margin % is 84.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current Net Margin % is 99.12%, which is near median its own 10-year median of 98.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Net Margin % of 99.12%. The current Net Margin % is 99.12%, which is near median its 10-year median of 98.22 and 16.8% above the Asset Management industry median of 84.90. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Net Margin % is 99.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score
Get the complete analysis for LSE:RTW
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
